Form 4: Boston Scientific EVP Wendy Carruthers Executes Stock Options and Sells Shares Under 10b5-1 Plan

EVP of Human Resources at Boston Scientific, Wendy Carruthers, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Summary

• Wendy Carruthers, EVP of Human Resources at Boston Scientific, filed a Form 4 detailing changes in beneficial ownership.
• On September 3, 2024, Carruthers exercised stock options to acquire 3,066 shares at $17.26 and 1,197 shares at $24.55.
• On the same day, Carruthers sold 6,983 shares of common stock at $81.7.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 17, 2023.
• Following these transactions, Carruthers directly owns 37,468 shares of common stock and holds options to purchase 25,972 additional shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the US market and provide transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without being accused of acting on inside information.

Comparison to Industry Standards

• Executives at comparable medical device companies such as Medtronic (MDT) and Abbott Laboratories (ABT) also routinely file Form 4s related to stock option exercises and sales.
• The use of 10b5-1 trading plans is a standard practice among executives in publicly traded companies to manage their stock holdings.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates this concern.

Key Dates